Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting
Clene Inc. (NASDAQ: CLNN) announced three presentations at the upcoming American Academy of Neurology Annual Meeting, scheduled for April 22-27, 2023, in Boston. The presentations will cover clinical trials demonstrating the efficacy and safety of their treatment CNM-Au8®. The studies include:
- VISIONARY-MS: A double-blind study on the efficacy of CNM-Au8 for relapsing multiple sclerosis, presented by Michael Barnett, Ph.D., on April 25.
- HEALEY ALS Trial: Results from the first four regimens of this platform trial, presented by Sabrina Paganoni, MD, Ph.D., also on April 25.
- Survival Benefit in ALS: Evidence for survival benefit with CNM-Au8 treatment, presented by James Berry, MD, MPH, on April 25.
These findings aim to support Clene's innovative approach in treating neurodegenerative diseases.
- Three presentations at the American Academy of Neurology Annual Meeting indicate strong clinical support for CNM-Au8.
- Evidence for survival benefit in ALS was presented, which could enhance market perception and investor confidence.
- None.
SALT LAKE CITY, April 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced three presentations at the upcoming 2023 American Academy of Neurology (AAN) Annual Meeting, taking place April 22-27, 2023, in Boston, MA. The platform presentations and poster highlight the results from three clinical trials that demonstrated clinical benefit and safety of treatment with CNM-Au8®.
Details of the three presentations are as follows:
Title: VISIONARY-MS Top-line Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis
Platform Session: PL5, Clinical Trials Plenary Session
Presenter: Michael Barnett, Ph.D.
Date & Time: Tuesday, April 25, 9:15 AM - 11:30 AM EST
Title: Results from the first four regimens of the HEALEY ALS Platform Trial
Platform Session: PL5, Clinical Trials Plenary Session
Presenter: Sabrina Paganoni, MD, Ph.D.
Date & Time: Tuesday, April 25, 9:15 AM - 11:30 AM EST
Title: Evidence for Survival Benefit in ALS with CNM-Au8 Treatment Across Three Study Populations
Poster Session: P8, Neuromuscular Disease: Amyotrophic Lateral Sclerosis 1
Presenter: James Berry, MD, MPH
Date & Time: Tuesday, April 25, 11:45 AM - 12:45 PM EST
The posters will be available in the Presentations section of the Clene website on April 25. section of the Clene website on April 25.
About CNM-Au8®
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc.
About Clene
Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Clene’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include our ability to demonstrate the efficacy and safety of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856
Media Contact
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310
FAQ
What will Clene present at the American Academy of Neurology Annual Meeting 2023?
When is Clene's presentation at the AAN Annual Meeting?
Who will present the VISIONARY-MS study results for Clene?
What is CNM-Au8 used for?
What evidence is presented regarding ALS and CNM-Au8?
